Show simple item record

dc.contributor.authorWestaby, D
dc.contributor.authorJimenez-Vacas, JM
dc.contributor.authorPadilha, A
dc.contributor.authorVarkaris, A
dc.contributor.authorBalk, SP
dc.contributor.authorde Bono, JS
dc.contributor.authorSharp, A
dc.date.accessioned2022-03-22T09:23:47Z
dc.date.available2022-03-22T09:23:47Z
dc.date.issued2021-12-23
dc.identifier.citationCancers, 2021, 14 (1)en_US
dc.identifier.issn2072-6694
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5042
dc.identifier.eissn2072-6694en_US
dc.identifier.eissn2072-6694
dc.identifier.doi10.3390/cancers14010051en_US
dc.identifier.doi10.3390/cancers14010051
dc.description.abstractDespite major improvements in the management of advanced prostate cancer over the last 20 years, the disease remains invariably fatal, and new effective therapies are required. The development of novel hormonal agents and taxane chemotherapy has improved outcomes, although primary and acquired resistance remains problematic. Inducing cancer cell death via apoptosis has long been an attractive goal in the treatment of cancer. Apoptosis, a form of regulated cell death, is a highly controlled process, split into two main pathways (intrinsic and extrinsic), and is stimulated by a multitude of factors, including cellular and genotoxic stress. Numerous therapeutic strategies targeting the intrinsic apoptosis pathway are in clinical development, and BH3 mimetics have shown promising efficacy for hematological malignancies. Utilizing these agents for solid malignancies has proved more challenging, though efforts are ongoing. Molecular characterization and the development of predictive biomarkers is likely to be critical for patient selection, by identifying tumors with a vulnerability in the intrinsic apoptosis pathway. This review provides an up-to-date overview of cell death and apoptosis, specifically focusing on the intrinsic pathway. It summarizes the latest approaches for targeting the intrinsic apoptosis pathway with BH3 mimetics and discusses how these strategies may be leveraged to treat prostate cancer.en_US
dc.formatElectronicen_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.titleTargeting the Intrinsic Apoptosis Pathway: A Window of Opportunity for Prostate Cancer.en_US
dc.typeJournal Article
dcterms.dateAccepted2021-12-15
rioxxterms.versionVoRen_US
rioxxterms.versionofrecord10.3390/cancers14010051en_US
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0en_US
rioxxterms.licenseref.startdate2021-12-23
dc.relation.isPartOfCancersen_US
pubs.issue1en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Translational Therapeutics
pubs.organisational-group/ICR/Students
pubs.organisational-group/ICR/Students/PhD and MPhil
pubs.organisational-group/ICR/Students/PhD and MPhil/20/21 Starting Cohort
pubs.publication-statusPublisheden_US
pubs.volume14en_US
pubs.embargo.termsNot knownen_US
icr.researchteamTranslational Therapeutics
dc.contributor.icrauthorWestaby, Danielen_US
dc.contributor.icrauthorSharp, Adamen_US


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/